Stock Groups

Australia’s CSL reaffirms commitment to making AstraZeneca COVID vaccine By Reuters

© Reuters. FILEPHOTO: Astra Zeneca Coronavirus vaccine Vaccine COVID-19 Coronavirus is Vaccine) and a syringe can be seen behind a visible AstraZeneca logo. This illustration was taken on March 14, 2021. REUTERS/Dado Ruvic/File Photo

(Reuters) – CSL, an Australian biotech company (OTC) stated on Thursday that it had committed to the agreement regarding production of approximately 50 million doses AstraZeneca’s COVID-19 vaccination vaccine through 2022.

After a media report claimed that Vaxzevria’s British-made vaccine would no longer be made in Australia because of high demand. Pfizer (NYSE,) Moderna (NASDAQ) [nL4N2R91XR]

Moderna and Pfizer have established market dominance using the mRNA-based COVID-19 vaccination technology to combat the pandemic.

CSL stated in a short statement that 20 million doses of drug have been manufactured and that it was expected to complete the remainder by the beginning of next year.

Sydney welcomes fully vaccinated people back to cafes and restaurants after almost four months lockdown.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.